CHEK2-related cancer predisposition

Summary

CHEK2-related cancer predisposition (MONDO:0700271) is a cancer caused by CHEK2 (GenCC Definitive), with 2 cohort genes (1 CIViC-evidence somatic driver; 279 ClinVar predisposition records).

At a glance

• Classification: Cancer
• Causal gene: CHEK2 (GenCC Definitive)
• Cohort genes: 2
• ClinVar variants: 279

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	CHEK2-related cancer predisposition
Mondo ID	MONDO:0700271
UMLS	C5882668
MedGen	1849727
GARD	0026411
Is cancer (heuristic)	yes

Data availability: 279 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary neoplastic syndrome › CHEK2-related cancer predisposition

Related subtypes (116): mosaic variegated aneuploidy syndrome, tuberous sclerosis, hereditary breast ovarian cancer syndrome, hereditary multiple osteochondromas, nevoid basal cell carcinoma syndrome, leukemia, chronic lymphocytic, susceptibility to, 2, blue rubber bleb nevus, cherubism, Beckwith-Wiedemann syndrome, multiple self-healing squamous epithelioma, erythroleukemia, familial, susceptibility to, goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, hyperparathyroidism 2 with jaw tumors, Kaposi sarcoma, susceptibility to, hereditary leiomyomatosis and renal cell cancer, susceptibility to uveal melanoma, melanoma and neural system tumor syndrome, nasopharyngeal carcinoma, susceptibility to, 2, WAGR syndrome, neuroblastoma, susceptibility to, 1, Rothmund-Thomson syndrome, mismatch repair cancer syndrome 1, Wiskott-Aldrich syndrome, N syndrome, hereditary thrombocytopenia and hematologic cancer predisposition syndrome, prostate cancer/brain cancer susceptibility, Brooke-Spiegler syndrome, pancreatic cancer, susceptibility to, 1, Carney-Stratakis syndrome, nasopharyngeal carcinoma, susceptibility to, 1, ovarian cancer, susceptibility to, 1, colorectal cancer, susceptibility to, 1, lung cancer susceptibility 1, leukemia, chronic lymphocytic, susceptibility to, 1, Kostmann syndrome, colorectal cancer, susceptibility to, 2, colorectal cancer, susceptibility to, 3, colorectal cancer, susceptibility to, 5, colorectal cancer, susceptibility to, 6, colorectal cancer, susceptibility to, 7, leukemia, chronic lymphocytic, susceptibility to, 3, leukemia, chronic lymphocytic, susceptibility to, 4, leukemia, chronic lymphocytic, susceptibility to, 5, lung cancer susceptibility 3, colorectal cancer, susceptibility to, 8, colorectal cancer, susceptibility to, 9, colorectal cancer, susceptibility to, 10, colorectal cancer, susceptibility to, 11, lung cancer susceptibility 4, neuroblastoma, susceptibility to, 3, neuroblastoma, susceptibility to, 4, neuroblastoma, susceptibility to, 5, neuroblastoma, susceptibility to, 6, leukemia, acute lymphocytic, susceptibility to, 1, leukemia, acute lymphocytic, susceptibility to, 2, lung cancer susceptibility 5, BAP1-related tumor predisposition syndrome, familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome, Maffucci syndrome, basal cell carcinoma, susceptibility to, 7, colorectal cancer, susceptibility to, 12, leukemia, acute lymphoblastic, susceptibility to, 3, cholangiocarcinoma, susceptibility to, progeroid features-hepatocellular carcinoma predisposition syndrome, neuroblastoma, susceptibility to, 7, DDX41-related hematologic malignancy predisposition syndrome, nasopharyngeal carcinoma, susceptibility to, 3, familial isolated hyperparathyroidism, intestinal polyposis syndrome, dyskeratosis congenita, familial rhabdoid tumor, multiple endocrine neoplasia, hereditary pheochromocytoma-paraganglioma, PTEN hamartoma tumor syndrome, familial multiple fibrofolliculoma, hereditary retinoblastoma, familial atypical multiple mole melanoma syndrome, hereditary nonpolyposis colon cancer, Li-Fraumeni syndrome, Cobb syndrome, neurofibromatosis, susceptibility to familial cutaneous melanoma, pancreatic cancer, susceptibility to, 5, leukemia, acute myeloid, susceptibility to, diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, glioma susceptibility, hemangioma, capillary infantile, susceptibility to, CDH1-related diffuse gastric and lobular breast cancer syndrome, NTHL1-deficiency tumor predisposition syndrome, SAMD9-related spectrum and myeloid neoplasm risk, neuroblastoma, susceptibility to, 2, BARD1-related cancer predisposition, BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, ATM-related cancer predisposition, PALB2-related cancer predisposition, RAD51C-related cancer predisposition, RAD51D-related cancer predisposition, Li-fraumeni-like syndrome, breast cancer, familial, susceptibility to, 1, breast cancer, familial, susceptibility to, 2, breast cancer, familial, susceptibility to, 3, colorectal cancer, susceptibility to, 4, colorectal cancer, susceptibility to, on chromosome 15, ovarian cancer, familial, susceptibility to, 1, ovarian cancer, familial, susceptibility to, 2, ovarian cancer, familial, susceptibility to, 3, inherited hematologic cancer-predisposing syndrome, mosaic neurofibromatosis/schwannomatosis, tumor predisposition syndrome 2, prostate cancer, hereditary, X-linked 3, follicular lymphoma, susceptibility to, GPR161-related medulloblastoma predisposition, SAMD9L-related spectrum and myeloid neoplasm risk, HAVCR2-related cancer predisposition, EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

279 retrieved; paginated sample, class counts are floors:

115 uncertain significance, 77 conflicting classifications of pathogenicity, 36 pathogenic/likely pathogenic, 17 pathogenic, 14 benign/likely benign, 11 likely pathogenic, 7 likely benign, 1 benign, 1 conflicting classifications of pathogenicity; risk factor

ClinVar	Variant (HGVS)	Gene	Classification	Review
1066705	NM_007194.4(CHEK2):c.684-2A>G	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1075895	NM_007194.4(CHEK2):c.724del (p.Thr242fs)	CHEK2	Pathogenic	criteria provided, multiple submitters, no conflicts
126914	NM_007194.4(CHEK2):c.444+1G>T	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
128042	NM_007194.4(CHEK2):c.1100del (p.Thr367fs)	CHEK2	Pathogenic	criteria provided, multiple submitters, no conflicts
128053	NM_007194.4(CHEK2):c.1263del (p.Ser422fs)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
128064	NM_007194.4(CHEK2):c.1555C>T (p.Arg519Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
128071	NM_007194.4(CHEK2):c.349A>G (p.Arg117Gly)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
128075	NM_007194.4(CHEK2):c.444+1G>A	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
128079	NM_007194.4(CHEK2):c.507del (p.Phe169fs)	CHEK2	Pathogenic	criteria provided, multiple submitters, no conflicts
133887	NM_007194.4(CHEK2):c.58C>T (p.Gln20Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
140772	NM_007194.4(CHEK2):c.283C>T (p.Arg95Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
141381	NM_007194.4(CHEK2):c.216T>G (p.Tyr72Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
141818	NM_007194.4(CHEK2):c.1169A>C (p.Tyr390Ser)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
142352	NM_007194.4(CHEK2):c.319+2T>A	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
142524	NM_007194.4(CHEK2):c.499G>A (p.Gly167Arg)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
142956	NM_007194.4(CHEK2):c.592+3A>T	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1453185	NM_007194.4(CHEK2):c.342G>A (p.Trp114Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1707509	NM_007194.4:c.(908+1_909-1)_(1095+1_1096-1)del	CHEK2	Pathogenic	criteria provided, single submitter
182430	NM_007194.4(CHEK2):c.793-1G>A	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
182450	NM_007194.4(CHEK2):c.1368dup (p.Glu457fs)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
182452	NM_007194.4(CHEK2):c.409C>T (p.Arg137Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
185097	NM_007194.4(CHEK2):c.902del (p.Leu301fs)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
187085	NM_007194.4(CHEK2):c.277del (p.Trp93fs)	CHEK2	Pathogenic	criteria provided, multiple submitters, no conflicts
187643	NM_007194.4(CHEK2):c.278G>A (p.Trp93Ter)	CHEK2	Pathogenic	criteria provided, multiple submitters, no conflicts
2116199	NM_007194.4(CHEK2):c.107del (p.Gln36fs)	CHEK2	Pathogenic	criteria provided, multiple submitters, no conflicts
2128744	NM_007194.4(CHEK2):c.1126G>T (p.Gly376Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
216003	NM_007194.4(CHEK2):c.593-1G>T	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
216652	NM_007194.4(CHEK2):c.846+4_846+7del	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
230455	NM_007194.4(CHEK2):c.1486C>T (p.Gln496Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
234505	NM_007194.4(CHEK2):c.1232G>A (p.Trp411Ter)	CHEK2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 10 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
CHEK2	Act	BRCA	CIViC #8950

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
CHEK2	Definitive	Autosomal dominant	CHEK2-related cancer predisposition	5

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CHEK2	Orphanet:1331	Familial prostate cancer
CHEK2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
CHEK2	Orphanet:440437	Familial colorectal cancer Type X
CHEK2	Orphanet:524	Li-Fraumeni syndrome
CHEK2	Orphanet:668	Osteosarcoma
COL11A1	Orphanet:2021	Fibrochondrogenesis
COL11A1	Orphanet:440354	Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome
COL11A1	Orphanet:560	Marshall syndrome
COL11A1	Orphanet:90635	Rare autosomal dominant non-syndromic sensorineural deafness type DFNA
COL11A1	Orphanet:90654	Stickler syndrome type 2

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CHEK2	HGNC:16627	ENSG00000183765	O96017	Serine/threonine-protein kinase Chk2	gencc,clinvar
COL11A1	HGNC:2186	ENSG00000060718	P12107	Collagen alpha-1(XI) chain	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CHEK2	Serine/threonine-protein kinase Chk2	Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks.
COL11A1	Collagen alpha-1(XI) chain	May play an important role in fibrillogenesis by controlling lateral growth of collagen II fibrils.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CHEK2	Kinase	yes	2.7.11.1	FHA_dom, Prot_kinase_dom, Ser/Thr_kinase_AS
COL11A1	Other/Unknown	no		Fib_collagen_C, Laminin_G, Collagen

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
lower esophagus mucosa	1
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
cartilage tissue	1
periodontal ligament	1
tibia	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CHEK2	183	ubiquitous	marker	primordial germ cell in gonad, lower esophagus mucosa, male germ line stem cell (sensu Vertebrata) in testis
COL11A1	209	broad	marker	tibia, cartilage tissue, periodontal ligament

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CHEK2	4,795
COL11A1	2,433

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CHEK2	O96017	38

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
COL11A1	P12107	53.06

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 15. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Stabilization of p53	1	380.7×	0.016	CHEK2
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	1	335.9×	0.016	CHEK2
Regulation of TP53 Activity through Methylation	1	271.9×	0.016	CHEK2
MET activates PTK2 signaling	1	190.3×	0.016	COL11A1
Regulation of TP53 Degradation	1	146.4×	0.016	CHEK2
Collagen chain trimerization	1	129.8×	0.016	COL11A1
Developmental Lineage of Pancreatic Ductal Cells	1	114.2×	0.016	COL11A1
Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A	1	102.0×	0.016	CHEK2
Assembly of collagen fibrils and other multimeric structures	1	100.2×	0.016	COL11A1
Collagen degradation	1	87.8×	0.016	COL11A1
Collagen biosynthesis and modifying enzymes	1	85.2×	0.016	COL11A1
Non-integrin membrane-ECM interactions	1	77.2×	0.016	COL11A1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	1	73.2×	0.016	CHEK2
G2/M DNA damage checkpoint	1	60.1×	0.017	CHEK2
Regulation of TP53 Activity through Phosphorylation	1	58.9×	0.017	CHEK2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of DNA damage checkpoint	1	2808.7×	0.006	CHEK2
tendon development	1	2106.5×	0.006	COL11A1
mitotic DNA damage checkpoint signaling	1	2106.5×	0.006	CHEK2
cellular response to bisphenol A	1	1685.2×	0.006	CHEK2
response to glycoside	1	1203.7×	0.006	CHEK2
proteoglycan metabolic process	1	936.2×	0.006	COL11A1
positive regulation of anoikis	1	936.2×	0.006	CHEK2
thymocyte apoptotic process	1	702.2×	0.006	CHEK2
regulation of autophagosome assembly	1	561.7×	0.006	CHEK2
replicative senescence	1	495.6×	0.006	CHEK2
chondrocyte development	1	468.1×	0.006	COL11A1
mitotic intra-S DNA damage checkpoint signaling	1	468.1×	0.006	CHEK2
detection of mechanical stimulus involved in sensory perception of sound	1	468.1×	0.006	COL11A1
cellular response to stress	1	421.3×	0.006	CHEK2
regulation of protein catabolic process	1	421.3×	0.006	CHEK2
signal transduction in response to DNA damage	1	401.2×	0.006	CHEK2
cartilage condensation	1	383.0×	0.006	COL11A1
ventricular cardiac muscle tissue morphogenesis	1	351.1×	0.007	COL11A1
cellular response to gamma radiation	1	300.9×	0.007	CHEK2
endodermal cell differentiation	1	247.8×	0.008	COL11A1
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	1	247.8×	0.008	CHEK2
DNA damage checkpoint signaling	1	195.9×	0.009	CHEK2
embryonic skeletal system morphogenesis	1	195.9×	0.009	COL11A1
regulation of signal transduction by p53 class mediator	1	191.5×	0.009	CHEK2
DNA damage response, signal transduction by p53 class mediator	1	179.3×	0.009	CHEK2
mitotic spindle assembly	1	172.0×	0.009	CHEK2
intrinsic apoptotic signaling pathway in response to DNA damage	1	162.0×	0.010	CHEK2
G2/M transition of mitotic cell cycle	1	156.0×	0.010	CHEK2
inner ear morphogenesis	1	150.5×	0.010	COL11A1
cellular response to xenobiotic stimulus	1	120.4×	0.011	CHEK2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CHEK2	NERATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CHEK2	30	4
COL11A1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NERATINIB	4	CHEK2
BOSUTINIB	4	CHEK2
BRIGATINIB	4	CHEK2
SUNITINIB	4	CHEK2
GEFITINIB	4	CHEK2
FASUDIL	3	CHEK2
CEDIRANIB	3	CHEK2
DOVITINIB	3	CHEK2
LESTAURTINIB	3	CHEK2
RUBOXISTAURIN	3	CHEK2
DORAMAPIMOD	2	CHEK2
FORETINIB	2	CHEK2
SU-014813	2	CHEK2
CENISERTIB	2	CHEK2
ILORASERTIB	2	CHEK2
CEP-11981	2	CHEK2
DEFOSBARASERTIB	2	CHEK2
PREXASERTIB	2	CHEK2
BI-2536	2	CHEK2
UCN-01	2	CHEK2
PF-00562271	1	CHEK2
KW-2449	1	CHEK2
RG-1530	1	CHEK2
MLN-8054	1	CHEK2
PF-03758309	1	CHEK2
SRA-737	1	CHEK2
SNS-314	1	CHEK2
CYC-116	1	CHEK2
GSK-690693	1	CHEK2
AST-487	1	CHEK2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CHEK2	690	Binding:687, Functional:2, ADMET:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
CHEK2	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CHEK2	690

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
NERATINIB	4	CHEK2
BOSUTINIB	4	CHEK2
BRIGATINIB	4	CHEK2
SUNITINIB	4	CHEK2
GEFITINIB	4	CHEK2
FASUDIL	3	CHEK2
CEDIRANIB	3	CHEK2
DOVITINIB	3	CHEK2
LESTAURTINIB	3	CHEK2
RUBOXISTAURIN	3	CHEK2
DORAMAPIMOD	2	CHEK2
FORETINIB	2	CHEK2
SU-014813	2	CHEK2
CENISERTIB	2	CHEK2
ILORASERTIB	2	CHEK2
CEP-11981	2	CHEK2
DEFOSBARASERTIB	2	CHEK2
PREXASERTIB	2	CHEK2
BI-2536	2	CHEK2
UCN-01	2	CHEK2
PF-00562271	1	CHEK2
KW-2449	1	CHEK2
RG-1530	1	CHEK2
MLN-8054	1	CHEK2
PF-03758309	1	CHEK2
SRA-737	1	CHEK2
SNS-314	1	CHEK2
CYC-116	1	CHEK2
GSK-690693	1	CHEK2
AST-487	1	CHEK2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	CHEK2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	COL11A1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
COL11A1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.